Company Overview of Organovo Holdings, Inc.
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dime...
6275 Nancy Ridge Drive
San Diego, CA 92121
Founded in 2007
Key Executives for Organovo Holdings, Inc.
Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee
Total Annual Compensation: $469.9K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $339.6K
Chief Technology Officer and Executive Vice President of Research & Development
Total Annual Compensation: $334.7K
Chief Strategy Officer and Executive Vice President of Pre-Clinical Development
Total Annual Compensation: $315.1K
Executive Vice President of Commercial Operations
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2015.
Organovo Holdings, Inc. Key Developments
Organovo Holdings, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 01:00 PM
Oct 2 15
Organovo Holdings, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 01:00 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Keith Murphy, Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee.
Organovo Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015
Aug 10 15
Organovo Holdings, Inc. announced unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported total revenues of USD 306,000 compared to USD 99,000 a year ago. Loss from operations was USD 8,458,000 compared to USD 6,410,000 a year ago. Net loss USD 8,491,000 or USD 0.10 per basic and diluted share compared to USD 6,433,000 or USD 0.08 per basic and diluted share a year ago. Net cash used in operating activities was USD 6,295,000 compared to USD 3,365,000 a year ago. Purchases of fixed assets were USD 1,135,000 compared to USD 238,000 a year ago.
Organovo Holdings, Inc. to Report Q1, 2016 Results on Aug 10, 2015
Aug 5 15
Organovo Holdings, Inc. announced that they will report Q1, 2016 results at 8:05 PM, GMT Standard Time on Aug 10, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|